<DOC>
	<DOC>NCT01480232</DOC>
	<brief_summary>This study is designed to evaluate the initial evidence for efficacy of the investigational medicine, EVP-6124, to improve smoking cessation outcomes with and without a standard taper of nicotine replacement therapy (NRT) in healthy nicotine dependent smokers</brief_summary>
	<brief_title>A Safety and Cognitive Function Study of EVP-6124 Versus Placebo in Subjects With Nicotine Dependence</brief_title>
	<detailed_description />
	<mesh_term>Tobacco Use Disorder</mesh_term>
	<mesh_term>Nicotine</mesh_term>
	<mesh_term>Nicotinic Agonists</mesh_term>
	<criteria>Selfreport of smoking an average of ≥10 cigarettes/day for 6 months and expired carbon monoxide (CO) ≥10 parts per million (ppm) or urine cotinine ≥ 100 ng/mL at screening or selfreport of smoking an average of 59 cigarettes/day for 6 months and a urine cotinine ≥30ng/ml at screening Have a negative urine drug screen at screening Fertile, sexually active subjects (males and females) must use an effective method of contraception from the first dose of study drug and for 3 months after the last dose of study drug If female and capable of conception, must have a negative urine Human chorionic gonadotrophin (hCG) pregnancy test at screening and Day 1 Have unstable medical illness with hospitalization for treatment likely within 6 months Have lifethreatening arrhythmia, cerebrovascular or cardiovascular event within 6 months of enrollment Have liver function tests elevated &gt;2.5 times the upper limit of normal range Have a tumor or a seizure disorder Currently using other tobacco or nicotinecontaining products and unwilling to try to quit Have a 6month history of substance use disorder other than nicotine or caffeine or major depressive disorder Have a history of multiple adverse drug reactions Nonresponse (past 3 months) to nicotine replacement therapy (NRT) &gt;20 mg/day, bupropion &gt;150 mg/day, or varenicline 2 mg/day for ≥4 weeks Use of excluded concomitant medications Hospitalization for any reason within 30 days of screening Use of any investigational drug or device within 30 days of screening Have clinically significant abnormal serum electrolytes Have insufficiently controlled diabetes mellitus Have renal insufficiency (serum creatinine &gt;1.8 mg/dL) Malignant tumor within the last 5 years, with the exception of squamous and basal cell carcinoma or cervical carcinoma in situ Have a clinically significant cardiovascular abnormality on the screening EKG Lifetime history of schizophrenia, bipolar disorder, posttraumatic stress disorder, bulimia, organic mental disorder, dementia, pervasive developmental disorder Have untreated, clinically significant hypothyroidism or hyperthyroidism Have a positive selfreport of human immunodeficiency virus infection Females who are pregnant or nursing Any experimental drug currently or within 30 days before baseline Have a serious risk of suicide Have a screening electrocardiogram (ECG) with a corrected QT (QTc) interval using Bazett's formula &gt;450 msec for males and &gt;470 msec for females or the presence of any clinically significant cardiac abnormalities</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>